Nicardipine Versus Labetalol During Intubation

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2009 by Seoul National University Bundang Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Seoul National University Bundang Hospital
ClinicalTrials.gov Identifier:
NCT01041066
First received: December 30, 2009
Last updated: NA
Last verified: September 2009
History: No changes posted
  Purpose

The aim of this study was to compare the efficacy of nicardipine and labetalol in attenuation of cardiovascular responses to endotracheal intubation.


Condition Intervention
Patients Who Are Intubated for General Anesthesia
Endotracheal Intubation
Drug: labetalol
Drug: nicardipine

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Investigator, Outcomes Assessor)
Primary Purpose: Prevention

Resource links provided by NLM:


Further study details as provided by Seoul National University Bundang Hospital:

Primary Outcome Measures:
  • hemodynamic variables (systolic blood pressure, diastolic blood pressure and mean blood pressure, heart rate) [ Time Frame: preinduction- 10 min after intubation ] [ Designated as safety issue: No ]

Estimated Enrollment: 70
Study Start Date: September 2009
Estimated Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: group L
0.4 mg/kg labetalol
Drug: labetalol
0.4 mg/kg labetalol intravenously 4 min before intubation
Active Comparator: group N
20 ㎍/kg nicardipine
Drug: nicardipine
20 ㎍/kg nicardipine intravenously 4 min before intubation

  Eligibility

Ages Eligible for Study:   20 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients scheduled for general anesthesia with endotracheal intubation

Exclusion Criteria:

  • Patients with heart failure or coronary artery disease 2-3 degree atrio-ventricular block or severe bradycardia (< 45 beats/min) asthma, bronchial spasm or chronic obstructive pulmonary disease patients with anticipated difficult intubation (Mallampati class III, IV) severe hepatic or renal dysfunction allergy or contraindication to study medication
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01041066

Contacts
Contact: Jung-Hee Ryu, Ph.D 82-31-787-7497 jinaryu@lycos.co.kr

Locations
Korea, Republic of
Seoul National University Bundang Hospital Recruiting
Seongnam-si, Gyeonggi-do, Korea, Republic of, 463-707
Contact: Jung-Hee Ryu, Ph.D    82-31-787-7497    jinaryu@lycos.co.kr   
Sponsors and Collaborators
Seoul National University Bundang Hospital
  More Information

No publications provided by Seoul National University Bundang Hospital

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Seoul National University Bundang Hospital
ClinicalTrials.gov Identifier: NCT01041066     History of Changes
Other Study ID Numbers: nicardipine-labetalol
Study First Received: December 30, 2009
Last Updated: December 30, 2009
Health Authority: Korea: Institutional Review Board

Keywords provided by Seoul National University Bundang Hospital:
patients who are intubated for general anesthesia

Additional relevant MeSH terms:
Labetalol
Nicardipine
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists
Calcium Channel Blockers
Membrane Transport Modulators
Vasodilator Agents

ClinicalTrials.gov processed this record on August 20, 2014